Nice rejects United Therapeutics’ cancer drug
pharmafile | July 15, 2016 | News story | Medical Communications, Research and Development | NICE, United Therapeutics, Unituxin, neuroblastoma
The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to treat a rare cancer affecting children saying the size of the benefits from the drug remained uncertain.
The regulator said it does not recommend the drug to treat high-risk neuroblastoma in children and young people aged 1–17 years whose disease has at least partially responded to induction chemotherapy, myeloablative therapy and autologous stem cell transplant.
Evidence from the trial showed the treatment caused a number of severe side effects including low blood pressure, pain, hypersensitivity and fever – although effects stopped when treatment did, Nice said in a statement.
Dinutuximab costs £6,390 per 17.5mg infusion, and a complete course of treatment (excluding those drugs it is given with) costs £127,800.
The regulator said the treatment did not meet the criteria to be considered for use in the Cancer Drugs Fund as it was not cost-effective, even with the patient access scheme discount proposed by the company, and the clinical uncertainties could not be addressed from further data collection within two years.
About 100 cases of neuroblastoma are diagnosed in the UK each year, with United Therapeutics estimating that 54 children in England and Wales would have been eligible for treatment with dinutuximab.
Anjali Shukla
Related Content

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …






